ECTRIMS 2024

Sep 17 - Sep 20, 2024 | Copenhagen, Denmark

Share this page

Close Tooltip
Copy Link Tooltip

Copy page URL

The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies

Authors Hauser SL, Giovannoni G, Filippi M, Weber MS, Montalban X, Nicholas JA, Schneble HM, Wang Q, Kappos L

Published date18 September, 2024

Early and sustained treatment of patients with MS with a high efficacy therapy delays disability progression and the time to reaching key long-term disability milestones. OCR has a robust long-term safety and efficacy experience across the MS spectrum. Results for OCR over eleven years are reported for 48-week CDP and other measures of progression (including the rate of repeated 48-week CDP, and the time to requiring walking aid or wheelchair) during OPERA I/II (NCT01247324/NCT01412333), ORATORIO (NCT01194570) and their open-label extensions.

Download Current View

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.